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Abstract
Background:	In	the	phase	3	B-	LONG	study	(NCT01027364),	prophylaxis	with	recom-
binant	factor	IX	Fc	fusion	protein	(rFIXFc)	every	7	to	>14	days	was	associated	with	
low	annualized	bleed	rates	(ABRs)	in	males	aged	≥12	years	with	severe	hemophilia	B.	
The	 long-	term	 safety	 and	 efficacy	 of	 rFIXFc	 prophylaxis	was	 confirmed	 in	 the	 B-	
YOND	study	(NCT01425723),	an	extension	of	the	B-	LONG	clinical	trial.
Objective:	The	aim	of	this	post-	hoc	analysis	was	to	evaluate	the	efficacy	of	a	≥14-	day	
rFIXFc	 dosing	 interval	 in	 patients	 treated	 prophylactically	 during	 B-	LONG	 or	
B-	YOND.
Methods:	The	analysis	included	22	patients	aged	≥12	years	who	received	prophylac-
tic	rFIXFc	with	a	≥14-	day	dosing	interval	at	any	time	during	B-	LONG	or	B-	YOND	up	
until	the	second	interim	analysis	of	B-	YOND	(September	2015).
Results:	The	median	(interquartile	range	[IQR])	rFIXFc	exposure	on	the	≥14-	day	dos-
ing	 interval	 was	 3.4	 (1.8-	4)	years.	 Patients	 treated	with	 a	 ≥14-	day	 dosing	 interval	
were	well	controlled	with	a	median	(IQR)	overall	ABR	of	1.6	(0.6-	2.7)	and	a	median	
(IQR)	spontaneous	ABR	of	0.7	(0.3-	1.1)	in	18	evaluable	patients.	A	rFIXFc	dosing	in-
terval	of	≥14	days	was	well	tolerated,	with	no	new	safety	concerns	identified.
Conclusion:	Most	patients	on	rFIXFc	prophylaxis,	with	a	dosing	interval	of	≥14	days,	
remained	well	controlled;	ABRs	were	consistent	with	those	reported	 in	the	overall	
study	population.	A	≥14-	day	dosing	interval	can	be	utilized	in	some	well	controlled	
individuals	and	reduces	the	burden	imposed	by	frequent	prophylactic	injections	while	
maintaining	adequate	bleed	suppression.
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1  | INTRODUCTION
Compared	with	on-	demand	treatment,	prophylactic	factor	replace-
ment	therapy	improves	clinical	outcomes	in	people	with	hemophilia,	
reducing	 the	 frequency	 of	 bleeding	 episodes,	 and	 improving	 joint	
outcomes	and	quality	of	life.1,2	For	prophylaxis	in	hemophilia	B,	the	
use	 of	 conventional	 half-	life	 factor	 IX	 (FIX)	 products	 requires	 fre-
quent	 injections	 to	maintain	protective	FIX	 levels.	The	burden	 im-
posed	by	frequent	injections	is	an	important	barrier	to	adherence	in	
individuals	with	hemophilia	treated	prophylactically.3
Recombinant	FIX	Fc	fusion	protein	(rFIXFc;	eftrenonacog	alfa)	is	
one	of	 the	approved	extended	half-	life	products	 for	hemophilia	B.	
rFIXFc	is	a	fusion	protein	comprising	human	coagulation	FIX	cova-
lently	bound	without	a	linker	to	the	Fc	domain	of	human	immuno-
globulin	G1	(IgG1)	produced	in	a	well-	characterized	human	cell	line.4 
The	Fc	portion	of	rFIXFc	binds	to	the	endogenous	neonatal	Fc	re-
ceptor	and	uses	the	IgG	recycling	pathway,	delaying	lysosomal	deg-
radation	of	Fc-	containing	proteins	by	recycling	them	back	 into	the	
circulation,	thereby	resulting	in	prolonged	half-	life	of	rFIXFc.4	rFIXFc	
is	approved	for	prophylaxis	and	treatment	of	bleeding	in	individuals	
of	all	age	groups	who	have	hemophilia	B.5
The	phase	3	B-	LONG	study	demonstrated	that	prophylaxis	with	
rFIXFc	 is	 associated	with	 low	 annualized	 bleeding	 rates	 (ABRs)	 in	
male	patients	aged	≥12	years	with	severe	hemophilia	B.6	The	exten-
sion	 study,	B-	YOND,	has	 confirmed	 the	 long-	term	safety	and	effi-
cacy	of	prophylaxis	with	rFIXFc7;	key	results	upon	completion	of	the	
B-	YOND	study	are	expected	in	2018.
The	 approved	 indication	 for	 rFIXFc	 in	 the	EU	was	 updated	 in	
July	2017	to	include	a	dosing	interval	of	≥14	days	for	use	in	patients	
with	 hemophilia	 B	 who	 are	 well	 controlled	 with	 rFIXFc	 adminis-
tered every 10 days.5	The	aim	of	the	current	post-	hoc	analysis	was	
to	characterize	long-	term	experience	with	extended	interval	dosing	
using	data	up	to	the	second	data	cut	of	B-	YOND	(September	2015).
2  | METHODS
B-	LONG	 (NCT01027364)	 was	 a	 phase	 3,	 non-	randomized,	 open-	
label,	 multicenter	 study,	 with	 primary	 and	 secondary	 endpoints	
reported	 previously.6	 The	 study	 enrolled	 123	male	 patients	 aged	
≥12	years	with	severe	hemophilia	B	(≤2%	of	normal	FIX	levels)	whose	
prior	treatment	regimen	was	either	prophylaxis	or	on	demand.
In	B-	LONG,	patients	were	assigned	to	one	of	four	treatment	groups:	
Group	1	received	prophylaxis	with	rFIXFc	50	IU/kg	weekly,	with	the	
dose	adjusted	as	needed	(n	=	63);	Group	2	received	prophylaxis	with	
rFIXFc	 100	IU/kg	 at	 an	 interval	 of	 every	 10	days,	 with	 the	 interval	
adjusted	as	needed	based	on	pharmacokinetics	(PK)	and/or	outcome	
(n	=	29);	 Group	 3	 received	 on-	demand	 treatment	 with	 rFIXFc	 20-	
100	IU/kg	for	bleeding	episodes,	with	the	dose	adjusted	according	to	
bleeding	severity	(n	=	27);	and	Group	4	received	treatment	with	rFIXFc	
as	part	of	perioperative	care	 (n	=	12).	The	primary	efficacy	endpoint	
in	B-	LONG	was	the	ABR,	and	primary	safety	endpoints	were	the	de-
velopment	of	inhibitors	(neutralizing	antibodies)	and	adverse	events.
B-	YOND	 (NCT01425723)	 was	 a	 non-	randomized,	 open-	label,	
extension	study	that	enrolled	patients	who	completed	B-	LONG6 or 
Kids	B-	LONG.8	Interim	data	from	October	2014	have	been	reported	
previously.7	Of	the	115	patients	who	completed	B-	LONG,	93	were	
enrolled	in	B-	YOND.	Data	from	patients	enrolled	in	B-	YOND	from	
B-	LONG	are	reported	in	this	post-	hoc	analysis;	patients	enrolled	in	
B-	YOND	from	Kids	B-	LONG	were	not	included	as	the	Kids	B-	LONG	
study	design	did	not	allow	dosing	intervals	longer	than	1	week.
There	were	 four	 treatment	 groups	 in	 B-	YOND:	 Group	 1	 received	
prophylaxis	with	rFIXFc	20-	100	IU/kg	every	7	days	(weekly	prophylaxis);	
Group	 2	 received	 interval-	adjusted	 prophylaxis	with	 rFIXFc	 100	IU/kg	
every	 8-	16	days	with	 dosing	 based	on	 the	 patient’s	 clinical	 profile	 ob-
served	in	the	parent	study	and	individual	PK	profile,	trough,	and/or	peak	
(recovery)	values;	Group	3	received	modified	prophylaxis	with	the	pos-
sibility	to	further	personalize	dosing	by	eg,	changing	dosing	frequency,	
adding	prevention	doses	before	strenuous	activities,	or	targeting	a	trough	
FIX	level	of	>5	IU/dL	if	warranted	by	bleeding	history	and/or	activity	level	
to	improve	prophylaxis;	and	Group	4	received	on-	demand	treatment.	The	
primary	endpoint	in	B-	YOND	was	the	development	of	inhibitors.
This	post-	hoc	analysis	included	patients	aged	≥12	years	who	re-
ceived	prophylactic	rFIXFc	with	a	dosing	interval	of	≥14	days	at	any	
time	during	B-	LONG	or	B-	YOND,	up	until	the	time	of	the	second	in-
terim	analysis	(September	2015;	see	Figure	1).	Descriptive	statistics	
were	used	to	summarize	data.
3  | RESULTS AND DISCUSSION
Twenty-	two	patients	 received	 rFIXFc	 prophylaxis	with	 a	 dos-
ing	 interval	 of	 ≥14	days	 at	 any	 time	 during	 B-	LONG	 or	 B-	
YOND,	until	 the	 time	of	 the	 second	 interim	B-	YOND	analysis	
(September	2015).	The	median	age	at	baseline	was	34.5	years	
with	 the	 vast	 majority	 of	 patients	 having	 <1%	 endogenous	
FIX	 activity.	 The	 median	 terminal	 half-	life	 (t½)	 of	 rFIXFc	 was	
99.8	hours	(Table	1).
The	 majority	 of	 patients	 (18	 of	 22)	 whose	 dosing	 interval	
was	extended	to	≥14	days	were	on	interval-	adjusted	prophylaxis	
Essentials
•	 Prophylactic	replacement	of	coagulation	factor	IX	(FIX)	is	recommended	in	severe	hemophilia	B.
•	 Recombinant	FIX	Fc	fusion	protein	(rFIXFc)	is	effective	and	well	tolerated.
•	 Phase	3	post-hoc	analysis	shows	that	some	patients	are	well	controlled	with	rFIXFc	every	≥14	days.
•	 A	≥14-day	rFIXFc	dosing	interval	may	help	reduce	treatment	burden	for	well-controlled	patients.
     |  111SHAPIRO et Al.
prior	 to	 the	 extension	 (Figure	1).	 The	 median	 (IQR)	 rFIXFc	 ex-
posure	 duration	 before	 extending	 the	 dosing	 interval	 was	 116	
(61-	205)	days,	 the	 median	 (IQR)	 weekly	 consumption	 was	 63	
(59-	72)	IU/kg,	 and	 the	 median	 (IQR)	 dosing	 interval	 was	 10	
(10-	12)	days.
Patients	had	a	median	rFIXFc	exposure	on	the	≥14-	day	dosing	
interval	of	3.4	years,	with	a	median	dose	per	injection	of	100	IU/
kg,	and	a	median	dosing	interval	of	14	days	(Table	2).	Six	patients	
had	dosing	intervals	that	extended	beyond	14	days:	1	on	15	days,	
3	on	16	days,	1	on	17	days,	 and	1	on	21	days.	The	median	 (IQR)	
trough	 level	 while	 on	 ≥14-	day	 dosing	was	 estimated	 to	 be	 2.80	
(2.3-	3.8)	IU/dL	based	on	149	measurements.
The	 majority	 of	 patients	 treated	 prophylactically	 appeared	
well	controlled	and	experienced	zero	bleeds	during	the	period	be-
fore	their	dosing	interval	was	extended	to	≥14	days.	However,	5	of	
22	patients	returned	permanently	to	a	dosing	interval	of	<14	days	
due	to	a	PK	result	(n	=	1),	patient	request	(n	=	3:	two	of	which	were	
for	personal	reasons,	the	third	due	to	bleeding),	or	repeated	bleed-
ing	(elbow;	n	=	1).	Among	these	five	patients,	one	had	previously	
been	treated	on-	demand	and	three	others	had	either	a	very	short	
or	no	observation	period	on	rFIXFc	prior	to	extending	the	dosing	
interval	and	 it	 is	 therefore	uncertain	 if	 these	patients	truly	were	
well	controlled	before	extending	their	dosing	interval	to	≥14	days.	
The	remaining	17	of	the	22	patients	(77.3%)	continued	on	a	dosing	
F IGURE  1 Study	flow	in	B-	LONG	and	the	B-	YOND	extension	study
Subjects aged ≥12 years with a dosing interval of ≥14
days at any time during this period (N = 22)
At the time of extending the dosing interval:
18 patients were treated with individualized prophylaxis
1 patient was on once-weekly prophylaxis
2 patients were treated on demand
1 patient started B-LONG on a 14-day interval
Phase 3 study Phase 3 extension study
Group 4: Perioperative treatment
Primary
completion
2012
Second interim
analysis
Sep 2015
First interim
analysis
Oct 2014
Start
2009
Group 3: On-demand treatment
Group 4: On-demand treatment
Group 2: Interval-adjusted prophylaxis
Group 1: Dose-adjusted weekly prophylaxis
Group 3: Modified prophylaxis
Group 2: Interval-adjusted prophylaxis
Group 1: Dose-adjusted weekly prophylaxis
B-LONG B-YOND
TABLE  1 Baseline	patient	characteristics
Characteristic 
Median (IQR) or n (%)
Patients treated with ≥14- day 
dosing interval, N = 22
Age,	y 34.5	(23-	48)
Race
White 13	(59.1)
Black 2	(9.1)
Asian 7	(31.8)
Other 0
Severity
<1%	endogenous	FIX	activity 20	(90.9)
1%-	2%	endogenous	FIX	activity 2	(9.1)
Genotype
Missense 16	(72.7)
Nonsense 1	(4.5)
Frameshift 1	(4.5)
Splice	mutation 2	(9.1)
Partial	gene	deletion 1	(4.5)
Large	deletions 0
Unknown 1	(4.5)
rFIXFc	t½,	h 99.8	(86.3-	105.9)
a
Data	represent	values	at	baseline	of	B-	LONG	for	patients	treated	with	
≥14-	day	dosing	interval	any	time	during	B-	LONG	or	B-	YOND,	until	the	
time	of	the	second	interim	B-	YOND	analysis.
FIX,	factor	IX;	IQR,	interquartile	range;	rFIXFc,	recombinant	factor	IX	Fc	
fusion	protein;	t½,	terminal	half-	life.
aGeometric	 mean	 calculations	 (as	 reported	 in	 B-	LONG6)	 are	 not	 pre-
sented	because	of	differences	in	sampling	profiles.	
TABLE  2 Exposure	to	rFIXFc	on	a	≥14-	day	dosing	interval
Parameter 
Median (IQR) N = 22
Exposure	duration,	days 1261	(648-	1448)
Exposure	days,	days 91	(69-	106)
Weekly	consumption,	IU/kg 50	(46-	51)
Dose	per	injection,	IU/kg 100	(92-	102)
Dosing	interval,	days 14	(14-	14)
IQR,	 interquartile	 range;	 rFIXFc,	 recombinant	 factor	 IX	 Fc	 fusion	
protein.
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interval	of	≥14	days	at	the	time	of	the	second	interim	data	cut,	al-
though	three	of	these	17	patients	had	had	a	temporary	reduction	
(50,	 30,	 and	22	days)	 in	 the	dosing	 interval	 to	<14	days	 at	 some	
point	 before	 the	 data	 cut	 because	 of	 bleeding	 (n	=	1),	 repeated	
bleeding	into	the	knee	following	arthroscopy	(n	=	1)	and	PK	result	
(n	=	1).
The	ABR	during	the	period	with	a	≥14-	day	dosing	 interval	was	
estimated	for	patients	on	prior	prophylaxis	who	had	an	observation	
period	 of	 ≥6	months	 on	 the	 extended	 dosing	 regimen.	 These	 pa-
tients	had	a	median	(IQR)	overall	ABR	of	1.6	(0.6-	2.7)	(Table	3),	which	
is	consistent	with	the	ABR	reported	for	the	overall	study	population.	
In	comparison,	the	median	(IQR)	overall	ABR	was	1.4	(0.0-	3.4)	with	
interval-	adjusted	 prophylaxis	 in	 B-	LONG,6	 2.25	 (0.87-	4.47)	 with	
interval-	adjusted	 prophylaxis	 and	 2.42	 (1.26-	5.40)	 with	 modified	
prophylaxis	the	interim	analysis	of	B-	YOND.7
The	 median	 (IQR)	 spontaneous	 ABR	 during	 the	 period	 with	 a	
≥14-	day	 dosing	 interval	was	 0.7	 (0.3-	1.1)	 (Table	3).	 This	 compares	
with	a	median	(IQR)	spontaneous	ABR	of	0.9	(0.0-	2.3)	with	interval-	
adjusted	 prophylaxis	 in	 B-	LONG,6	 0.68	 (0-	2.58)	 with	 interval-	
adjusted	prophylaxis	and	0.41	(0-	1.84)	with	modified	prophylaxis	in	
the	interim	analysis	in	B-	YOND.7	These	data	provide	further	support	
that	patients	with	hemophilia	B	can	remain	well	controlled	with	an	
individualized	14-	day	dosing	interval.
In	total,	four	patients	were	excluded	from	the	ABR	calculation;	
two	because	they	had	an	observation	period	that	was	too	short	(28	
and	57	days)	 to	 obtain	 robust	 estimates	of	ABR	 and	 an	 additional	
two	patients	because	they	had	received	on-	demand	treatment	be-
fore	the	dosing	interval	was	changed	to	≥14	days.
A	 total	 of	 120	bleeding	 episodes	 in	22	patients	occurred	over	
744	patient	months	of	exposure	while	on	a	≥14-	day	dosing	interval.	
Approximately	60%	of	the	bleeds	occurred	during	the	first	10	days	
since	previous	dosing.	The	majority	of	bleeding	episodes	(114	[95%])	
were	controlled	with	either	one	or	two	injections.	The	median	(IQR)	
total	rFIXFc	dose	used	to	treat	a	bleed	was	56.3	(37-	99.1)	IU/kg.
The	adverse	event	profile	was	consistent	with	that	expected	in	
a	hemophilia	B	population,	and	no	new	safety	concerns	were	identi-
fied,	compared	with	the	overall	populations	in	B-	LONG6	or	B-	YOND.7 
There	were	no	reports	of	serious	allergic	reactions,	anaphylaxis,	vas-
cular	thrombotic	events,	or	development	of	inhibitors.6,7
In	 conclusion,	 these	data	 confirm	 that	 patients	who	were	well	
controlled	 on	 a	 10-	day	 dosing	 interval	 of	 rFIXFc	 prophylaxis	 re-
mained	well	 controlled	with	 low	ABRs	when	 treated	 long-	term	on	
a	≥14-	day	dosing	interval,	and	the	treatment	was	well	tolerated.	A	
rFIXFc	dosing	interval	of	≥14	days	allows	for	broader	treatment	flex-
ibility	and	treatment	 individualization	compared	with	conventional	
FIX	products,	and	 further	 reduces	 the	burden	 for	patients,	poten-
tially	positively	impacting	adherence.
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